Metropolis Healthcare Limited has submitted its quarterly compliance certificate to stock exchanges for the quarter ended March 31, 2026, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018. The filing, dated April 07, 2026, confirms the company's adherence to prescribed dematerialisation processes and securities handling procedures.

Regulatory Compliance Certificate

The certificate was issued by MUFG Intime India Private Limited, formerly known as Link Intime India Private Limited, which serves as the company's Registrar and Transfer Agent. This document specifically addresses compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, covering the quarter ended March 31, 2026.

Dematerialisation Process Confirmation

The registrar confirmed that all securities received from depository participants for dematerialisation during the quarter were properly processed within prescribed timelines. The certificate validates that securities received for dematerialisation were appropriately confirmed or rejected to the depositories, with proper substitution of depository names in the member register.

Key aspects of the compliance confirmation include:

• Proper handling of securities received for dematerialisation
• Timely confirmation or rejection to depositories
• Appropriate mutilation and cancellation of physical certificates
• Substitution of depository names as registered owners within prescribed timelines

Filing Details and Authorization

The submission was authorized by Kamlesh C Kulkarni, Head – Legal & Secretarial at Metropolis Healthcare Limited, with digital signature authentication completed on April 07, 2026. The certificate from MUFG Intime India was signed by Ashok Shetty, Sr. Vice President-Corporate Registry, dated April 01, 2026.

This quarterly filing represents standard regulatory compliance for listed companies, ensuring transparency in securities handling and maintaining investor confidence in the dematerialisation process. The certificate confirms that all securities transactions during Q4FY26 were conducted in accordance with SEBI regulations and established market practices.

Metropolis healthcare Limited has released its business update for the quarter ended March 31, 2026, showcasing strong operational performance with consolidated revenue growth of ~23% on a year-on-year basis. The update, filed under Regulation 30 of SEBI regulations, highlights robust momentum across key business segments and channels.

Strong Revenue Performance Across Segments

The company's consolidated performance for Q4FY26 demonstrates significant growth momentum across multiple business verticals. The ~23% year-on-year revenue growth includes contributions from recent acquisitions including Core Diagnostics, Scientific Pathology, Dr. Ahuja's Pathology & Imaging Center (DAPIC), and Dr. RS Patil's Ambika Pathology Laboratory (Ambika).

Acquisition Integration Shows Positive Results

The company's recent acquisitions are demonstrating successful integration with tangible synergy benefits. Core Diagnostics has shown margin improvement, reaching the high single-digit range in Q4FY26. The acquired entities DAPIC, Scientific, and Ambika continue to deliver margins higher than the company's average, contributing positively to overall profitability.

The strong B2B revenue growth of ~30% was particularly driven by specialty growth and higher B2B contribution from Core Diagnostics, indicating successful cross-selling and market expansion strategies.

Organic Growth Momentum Continues

Excluding recent acquisitions, Metropolis Healthcare's organic business achieved ~14.5% year-on-year revenue growth in Q4FY26. This organic growth was primarily driven by:

• Increased patient volumes
• Higher test volumes
• Improved product mix

The company also reported improved EBITDA margins for the quarter on a year-on-year basis, attributed to operating leverage and efficiency gains across operations.

Wellness and Specialty Segments Drive Growth

The TruHealth wellness segment recorded ~25% growth on a year-on-year basis, while specialty segments achieved ~29% growth during Q4FY26. This performance reflects the company's strategic focus on high-value testing services and preventive healthcare solutions.

The balanced growth across both B2B and B2C channels, supported by volume increases and product mix improvements, demonstrates the company's diversified revenue approach and market penetration capabilities.

Regulatory Compliance and Future Outlook

The business update was filed in accordance with SEBI regulations and the company's Code of Fair Disclosure. The quarterly update is presented on a consolidated basis, with financial results for Q4FY26 subject to audit. A detailed information update will follow once the Board of Directors approves the complete financial results for the quarter.